Ovid Therapeutics Inc. (OVID) stock
Close on Nov 17, 2026Market cap $433.56MP/E –Yield –
Earnings
Ovid Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Ovid Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 17, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026before the open | – | – | -$0.10 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 18, 2026before the open | $700.00K | +821.1% | $0.06 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | – | – | -$0.17 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025before the open | – | – | -$0.14 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 11, 2025before the open | $76.00K | – | -$0.13 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024before the open | – | – | -$0.17 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 8, 2024before the open | – | – | -$0.22 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 3, 2023before the open | – | – | -$0.16 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 4, 2023before the open | $75.00K | – | -$0.18 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 5, 2023before the open | $66.16K | -95.3% | -$0.19 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 13, 2023before the open | $46.28K | – | -$0.16 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $11.10K | – | -$0.17 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | – | – | -$0.21 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022before the open | $1.40M | – | -$0.23 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 15, 2022before the open | – | – | -$0.38 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | – | – | -$0.17 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 16, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 15, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020during market hours | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 7, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 11, 2020before the open | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 8, 2019before the open | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 7, 2019during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Ovid Therapeutics guided for has been reported
Guidance history
Every forecast Ovid Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 10, 2021 | non-GAAP adjusted operating expenses | Q4 FY2021 | $8.00M – $10.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Ovid Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- News
- News
- Results
- Results
- News
- Update
- Results
- Results
- Results
- Update
- News
See a number that looks wrong?